Loading
A phase 2 trial of Zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine in diffuse large b-cell lymphoma and mantle cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.
DALY II USA/ MB-CART2019.1 for DLBCL is a phase 2 interventional study registered as NCT04792489 by Miltenyi Biomedicine GmbH, with 315 participants planned, started 2021-05-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine. Conditions listed: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Diffuse large B-cell lymphoma.
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Bendamustine, Diffuse large B-cell lymphoma.
Shares Fludarabine, Mantle cell lymphoma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Bendamustine, Mantle cell lymphoma, Diffuse large B-cell lymphoma.
Shares Bendamustine, Fludarabine.
Shares Bendamustine, Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/